- Home
- VIGL vs MNOV Comparison
VIGL vs MNOV Comparison
Compare VIGL & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- MNOV
- Stock Information
- Founded
- VIGL 2020
- MNOV 2000
- Country
- VIGL United States
- MNOV United States
- Employees
- VIGL N/A
- MNOV N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- MNOV Health Care
- Exchange
- VIGL Nasdaq
- MNOV Nasdaq
- Market Cap
- VIGL 134.9M
- MNOV 68.2M
- IPO Year
- VIGL 2022
- MNOV 2005
- Fundamental
- Price
- VIGL $8.05
- MNOV $1.27
- Analyst Decision
- VIGL Buy
- MNOV Strong Buy
- Analyst Count
- VIGL 7
- MNOV 2
- Target Price
- VIGL $8.00
- MNOV $7.00
- AVG Volume (30 Days)
- VIGL 1.1M
- MNOV 17.6K
- Earning Date
- VIGL 08-12-2025
- MNOV 08-07-2025
- Dividend Yield
- VIGL N/A
- MNOV N/A
- EPS Growth
- VIGL N/A
- MNOV N/A
- EPS
- VIGL N/A
- MNOV N/A
- Revenue
- VIGL N/A
- MNOV N/A
- Revenue This Year
- VIGL N/A
- MNOV N/A
- Revenue Next Year
- VIGL N/A
- MNOV N/A
- P/E Ratio
- VIGL N/A
- MNOV N/A
- Revenue Growth
- VIGL N/A
- MNOV N/A
- 52 Week Low
- VIGL $1.31
- MNOV $1.12
- 52 Week High
- VIGL $8.06
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- VIGL 88.18
- MNOV 40.89
- Support Level
- VIGL $7.86
- MNOV $1.32
- Resistance Level
- VIGL $8.05
- MNOV $1.38
- Average True Range (ATR)
- VIGL 0.02
- MNOV 0.05
- MACD
- VIGL -0.15
- MNOV -0.00
- Stochastic Oscillator
- VIGL 73.15
- MNOV 15.38
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.